| Item Type | Name |
|
Concept
|
Pyrazoles
|
|
Academic Article
|
A potential role of ruxolitinib in leukemia.
|
|
Academic Article
|
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
|
|
Academic Article
|
Breakthroughs in myeloproliferative neoplasms.
|
|
Academic Article
|
Efficacy of ruxolitinib for myelofibrosis.
|
|
Academic Article
|
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
|
|
Academic Article
|
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
|
|
Academic Article
|
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
|
|
Academic Article
|
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
|
|
Academic Article
|
Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
|
|
Academic Article
|
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
|
|
Academic Article
|
Emerging drugs for myelofibrosis.
|
|
Academic Article
|
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
|
|
Academic Article
|
Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.
|
|
Academic Article
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
|
Academic Article
|
Ruxolitinib for the treatment of myelofibrosis.
|
|
Academic Article
|
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
|
|
Academic Article
|
Ruxolitinib: the first agent approved for myelofibrosis.
|
|
Academic Article
|
Advances in the management of myelofibrosis.
|
|
Academic Article
|
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
|
|
Academic Article
|
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
|
|
Academic Article
|
Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.
|
|
Academic Article
|
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
|
|
Academic Article
|
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
|
|
Academic Article
|
Changing myelofibrosis's natural course at last.
|
|
Academic Article
|
Therapeutic potential of JAK2 inhibitors.
|
|
Academic Article
|
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
|
|
Academic Article
|
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.
|
|
Academic Article
|
Practical management of patients with myelofibrosis receiving ruxolitinib.
|
|
Academic Article
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
|
Academic Article
|
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
|
|
Academic Article
|
Ruxolitinib and survival improvement in patients with myelofibrosis.
|
|
Academic Article
|
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.
|
|
Academic Article
|
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
|
|
Academic Article
|
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
|
|
Academic Article
|
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
|
|
Academic Article
|
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
|
|
Academic Article
|
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
|
|
Academic Article
|
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
|
|
Academic Article
|
Ruxolitinib for the treatment of patients with polycythemia vera.
|
|
Academic Article
|
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.
|
|
Academic Article
|
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
|
|
Academic Article
|
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
|
|
Academic Article
|
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
|
|
Academic Article
|
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
|
|
Academic Article
|
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib.
|
|
Academic Article
|
New therapies for polycythemia vera.
|
|
Academic Article
|
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.
|
|
Academic Article
|
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
|
|
Academic Article
|
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
|
|
Academic Article
|
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
|
|
Academic Article
|
Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
|
|
Academic Article
|
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
|
|
Academic Article
|
Ruxolitinib dose management as a key to long-term treatment success.
|
|
Academic Article
|
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
|
|
Academic Article
|
Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.
|
|
Academic Article
|
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
|
|
Academic Article
|
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
|
|
Academic Article
|
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
|
|
Academic Article
|
Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
|
|
Academic Article
|
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
|
|
Academic Article
|
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
|
|
Academic Article
|
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
|
|
Academic Article
|
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
|
|
Academic Article
|
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
|
|
Academic Article
|
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
|
|
Academic Article
|
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
|
|
Academic Article
|
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
|
|
Academic Article
|
Developmental Therapeutics in Myeloproliferative Neoplasms.
|
|
Academic Article
|
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
|
|
Academic Article
|
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
|
|
Academic Article
|
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
|
|
Academic Article
|
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
|
|
Academic Article
|
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
|
|
Academic Article
|
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
|
|
Academic Article
|
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
|
|
Academic Article
|
Management of Myelofibrosis-Related Cytopenias.
|
|
Academic Article
|
Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
|
|
Academic Article
|
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
|
|
Academic Article
|
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
|
|
Academic Article
|
Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
|
|
Academic Article
|
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
|
|
Academic Article
|
New Concepts of Treatment for Patients with Myelofibrosis.
|
|
Academic Article
|
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
|
|
Academic Article
|
Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.
|
|
Academic Article
|
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
|
|
Academic Article
|
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
|
|
Academic Article
|
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
|
|
Academic Article
|
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
|
|
Academic Article
|
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
|
|
Academic Article
|
Management of myelofibrosis after ruxolitinib failure.
|
|
Academic Article
|
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
|
|
Academic Article
|
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
|
|
Academic Article
|
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.
|
|
Academic Article
|
Avapritinib for Systemic Mastocytosis.
|
|
Academic Article
|
Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice.
|
|
Academic Article
|
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
|
|
Academic Article
|
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
|
|
Academic Article
|
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100???109/L): Final Analysis of an Open-Label Phase 2 Study.
|
|
Academic Article
|
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
|
|
Academic Article
|
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
|
|
Academic Article
|
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
|
|
Academic Article
|
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
|
|
Academic Article
|
Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life.
|
|
Academic Article
|
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.
|
|
Academic Article
|
Phase III MANIFEST-2: pelabresib?+ ruxolitinib vs placebo?+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
|
|
Academic Article
|
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
|
|
Academic Article
|
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
|